ArticleCureus2025
Metastatic Adenocarcinoma of the Prostate Presenting as a Penile Mass in a Patient With Acute Urinary Retention: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic prostate adenocarcinoma presenting as a penile lesion is extremely rare and can mimic primary penile malignancies. A 72-year-old male presented with acute urinary retention and a painless penile lesion with phimosis. The lesion had gradually enlarged over six months with intermittent bleeding. Examination revealed a 3 cm ulcerated mass on the glans near the coronal sulcus. A wedge biopsy suggested adenosquamous carcinoma. CT showed no distant metastases. The patient underwent total penectomy with perineal urethrostomy. Histopathology revealed malignancy with clear margins. Further evaluation at a major tertiary health care centre, including immunohistochemistry, confirmed metastatic prostatic adenocarcinoma (NKX3.1, PSA positive; CK7, CK20, CDX2 negative). Serum prostate-specific antigen (PSA) was elevated (37.8 ng/mL), and prostate-specific membrane antigen positron emission tomography (PSMA PET) confirmed metastasis. The patient was treated with androgen deprivation therapy (bilateral orchidectomy), abiraterone, and docetaxel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.